CAR T-Cell Therapy for Rheumatoid Arthritis

Researchers at Charité - Universitätsmedizin Berlin have successfully utilized CD19 CAR T-cell therapy, originally developed for cancer treatment, to reset the immune system in patients with severe, treatment-refractory rheumatoid arthritis. Published on September 13, 2026, a phase 1 clinical trial named COMPARE evaluated six adults aged 31 to 69 who had exhausted up to eight prior targeted or biologic therapies over a decade without relief. The investigators sought to determine whether genetically reprogramming a patient's own T cells to target CD19-positive B cells could eliminate disease-driving memory cells hidden deep within tissues like bone marrow, lymph nodes, and joint linings. A single infusion preceded by a brief course of preparatory chemotherapy led to marked clinical improvements and sustained medication-free remission in three of the six participants during a one-year follow-up period. The mechanism centers on erasing pathological immune memory by depleting harmful B cells and allowing the immune system to rebuild predominantly from naive B cells that lack disease-shaping experiences. While adverse events were limited to a temporary, mild-to-moderate cytokine release syndrome with no severe neurological complications or infections, the small sample size necessitates broader validation. Phase 2 of the trial will expand to ten additional patients and compare the engineered cell therapy directly against approved B-cell-targeting rheumatoid arthritis medications to confirm whether deep, durable disease modification can safely replace lifelong conventional immune suppression.